This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Rheumatology  • Osteoporosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Robert P. Heaney, MD

JAMA. 1998;280:2119-2120.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The explosion of osteoporosis-related diagnostic and therapeutic options in the past 6 to 10 years has created its own challenges. Guidelines have recently been published concerning who should be tested¹ but, in a sense, that issue is moot. Bone mass measurement technology is proliferating rapidly, and physicians increasingly are confronted with ostensibly healthy individuals who bring them a printout showing that they have low bone mass. Should the physician recommend one of the growing array of bisphosphonates, selective estrogen receptor modulators, hormone replacement therapy regimens, or dietary supplements? Normally, the clinician treats the patient, not a test, but when it comes to prevention, the test result may be all the physician has to go on.

Osteoporosis is now defined as a condition of skeletal fragility due to low bone mass, microarchitectural deterioration of bone tissue, or both.² This important revision emphasizes the fragility and relegates bone . . . [Full Text of this Article]

From Creighton University, Omaha, Neb.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Alendronate and Fracture Prevention
, , , , , and
JAMA. ;282():324-325.
FULL TEXT  

RELATED ARTICLE

Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures: Results From the Fracture Intervention Trial
, , , , , , , , , , , , , , and
JAMA. ;280():2077-2082.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint
Marcus et al.
Endocr. Rev. 2002;23:16-37.
ABSTRACT | FULL TEXT  

Alendronate and Fracture Prevention
Cummings et al.
JAMA 1999;282:324-325.
FULL TEXT  

Alendronate Reduces Fracture Risk in Women With Low Bone Density
JWatch General 1999;1999:1-1.
FULL TEXT